OncClubAll Oncology NewsPipeline Report
InsightsMedical World NewsOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsThe Talk
Conference CoverageConference Listing
Giants of Cancer CarePER EventsScientific InterchangesState of the Science Summit / IPCWebinars
Partners
Oncology Live®Oncology FellowsSupplements And Featured PublicationsAll Publications
CME/CE
Biomarker ConsortiumInteractive ToolsLearning ModulesPresentationsSponsored
Print SubscriptioneNewsletter
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
Spotlight -
  • REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Share your views with OncChats
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
    • Partners
    • CME/CE
Advertisement

Emerging Treatment Paradigms for Advanced Lung Cancer

home / peer-exchange / advanced-lung-cancer-emerging-treatment
Advertisement
Impact of PACIFIC Trial on Locally Advanced NSCLC

EP. 1: Impact of PACIFIC Trial on Locally Advanced NSCLC

February 26th 2019
The Role of Surgery in NSCLC Following PACIFIC Trial

EP. 2: The Role of Surgery in NSCLC Following PACIFIC Trial

February 26th 2019
Imaging Schedule Following CRT in Locally Advanced NSCLC

EP. 3: Imaging Schedule Following CRT in Locally Advanced NSCLC

February 26th 2019
Biomarker Testing in Stage III NSCLC

EP. 4: Biomarker Testing in Stage III NSCLC

February 26th 2019
Driver Mutations Trump PD-L1 Expression in Lung Adenocarcinoma

EP. 5: Driver Mutations Trump PD-L1 Expression in Lung Adenocarcinoma

February 26th 2019
Choosing Therapy for Newly Diagnosed NonDriver NSCLC

EP. 6: Choosing Therapy for Newly Diagnosed NonDriver NSCLC

February 26th 2019
Advertisement
Looking at the IMpower Data in NSCLC

EP. 7: Looking at the IMpower Data in NSCLC

February 26th 2019
CheckMate-227 and the Role of TMB in NSCLC

EP. 8: CheckMate-227 and the Role of TMB in NSCLC

February 26th 2019
Treatment Options for mNSCLC After Progression

EP. 9: Treatment Options for mNSCLC After Progression

February 26th 2019
A Win for Small-Cell Lung Cancer: IMPOWER 133

EP. 10: A Win for Small-Cell Lung Cancer: IMPOWER 133

February 26th 2019
ADRIATIC Trial in Locally Advanced Small-Cell Lung Cancer

EP. 11: ADRIATIC Trial in Locally Advanced Small-Cell Lung Cancer

February 26th 2019
Molecular Testing for NSCLC in 2019

EP. 12: Molecular Testing for NSCLC in 2019

February 26th 2019
Advertisement
Osimertinib, the Standard for EGFR+ NSCLC

EP. 13: Osimertinib, the Standard for EGFR+ NSCLC

February 26th 2019
Resistance Mechanisms in EGFR+ NSCLC

EP. 14: Resistance Mechanisms in EGFR+ NSCLC

February 26th 2019
Available Therapies for ALK-Rearranged NSCLC

EP. 15: Available Therapies for ALK-Rearranged NSCLC

February 26th 2019
A Game-Changing Year for NSCLC

EP. 16: A Game-Changing Year for NSCLC

February 26th 2019

Latest Conference Coverage

Isa-KRd Elicits MRD-Negative Remissions in Newly Diagnosed, High-Risk Myeloma

KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis

Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact